SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending intensely right now ahead of its earnings report, with community focus on its massive AI infrastructure investments and significant debt levels. Investors are debating if robust cloud growth and demand for AI compute will offset concerns over capital expenditure and conflicting reports about the status of a major data center expansion deal.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after reporting its first-ever quarterly profit and strong delivery guidance, marking a significant turnaround that has the community anticipating a potential short squeeze. Investors are highlighting the company's battery-as-a-service model and new in-house chip developments, drawing comparisons to other major EV players' early growth.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is actively discussed following an earnings miss and reduced fiscal guidance, fueling a steep sell-off. While some in the community highlight robust demand for drone solutions amid global conflicts and the company's ongoing contract negotiations, others express concern over valuation and acquisition integration.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is trending following its transformative $615 million acquisition of Covelya Group, immediately scaling the company into a comprehensive subsea robotics platform with expanded global capabilities in defense, offshore energy, and ocean science. The community remains highly bullish despite recent share dilution, focusing on its strategic vertical integration, crucial role in maritime security amid geopolitical tensions, and the potential for a future NASDAQ uplisting to unlock significant institutional investment.

Hydrograph Clean Power, Inc. engages in the research, development, marketing and commercialization of patented technology to produce pristine graphene, graphene derivatives and services. The company was founded by Harold Charles Davidson on June 26, 2017 and is headquartered in Vancouver, Canada.

Hydrograph Clean Power Inc

Hydrograph Clean Power (HGRAF) is trending as its high-purity graphene secures key regulatory approvals and a new Austin production facility nears operation, fueling investor speculation around upcoming contracts and an anticipated NASDAQ uplisting, despite community discussions on its high valuation before significant revenue.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is trending following its recent positive financial results, which reported increased North America local revenue and billings, fueling a turnaround narrative. Community discussion is sharply divided between those anticipating a short squeeze due to high short interest and its valuable SumUp stake, and skeptics who view the stock as fundamentally overvalued and manipulated.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending sharply as Novo Nordisk dropped its patent lawsuit, paving the way for Hims to sell Ozempic and Wegovy, sparking intense community discussion about a potential short squeeze and a re-evaluation of its long-term growth in the GLP-1 market.

CitroTech, Inc. is an integrated environmental service company, which engages in the provision of field services, remediation transportation, and EHS compliance services. It also offers on-site technical services, on-site and off-site treatment for hazardous and non-hazardous waste. The company was founded on March 14, 1990 and is headquartered in Cheyenne, WY.

CitroTech Inc.

CitroTech is drawing strong attention and trading volume following its virtual investor conference, with the community focused on its unique EPA Safer Choice certified fire retardant technology as a significant regulatory moat and its potential in the expanding wildfire prevention and building materials sectors.

The Beachbody Co., Inc. operates as a health and wellness company. It offers holistic health and wellness platforms. The company's product offerings include digital subscriptions, nutritional products, and connected fitness products. Digital subscriptions include Beachbody On Demand (BOD) and Openfit. The subscriptions are renewed on a monthly, quarterly, or annual basis and include unlimited access to a library of live and on-demand fitness and nutrition content. Nutritional products include Shakeology, Beachbody Performance supplements, BEACHBARs, and others. Connected fitness products include The Beachbody Bike (also known as Myx), which is equipped with a swivel touch screen that enables users to engage with content beyond the indoor cycling experience and encourages broader cross-training, incorporating resistance training and yoga for a more holistic fitness experience and healthier results. The company was founded by Carl Daikeler and Jon Congdon in 1998 and is headquartered in El Segundo, CA.

Beachbody Company Inc (The) - Ordinary Shares - Class A

BODI is trending as its recent financial results, showing positive adjusted EBITDA and projected positive cash flow, fuel speculation of a turnaround for the fitness company. This has ignited a split in the community, with some anticipating a recovery while long-term investors remain deeply wary of past dilution and management's promises.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as the community eagerly awaits a Supreme Court decision on its patent infringement case, which could clarify 'skinny label' use, while simultaneously digesting a strategic exclusion from China's NRDL designed to preserve pricing. This legal and market positioning, coupled with recently announced positive cash flow and upcoming investor meetings, intensifies ongoing buyout speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Going On With CRISPR Therapeutics Stock Today?

CRISPR Therapeutics fell Tuesday after unveiling a $350 million convertible notes offering, overshadowing recent momentum from Casgevy uptake and fourth-quarter revenue growth.read more...

CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap Down - What's Next?

CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap Down - What's Next...

<ul class="summary-bullets"><li>CRISPR Therapeutics said the debt securities will rank as senior unsecured obligations.</li><li>Interest payments will be made twice each year, with the first scheduled payment expected in September 2026.</li><li>In January, the company said it had around $2 billion in cash, cash equivalents, and marketable securities.</li></ul>CRISPR Therapeutics AG (CRSP) on Tuesday announced plans to raise capital through a private debt offering as the gene-editing biotechnology company continues funding research and development efforts.&nbsp;The company said it intends to issue $350 million in convertible senior notes, scheduled to mature in 2031, subject to prevailing market conditions and investor demand.<h2 class="st-heading-2">Structure Of The Convertible Notes</h2>According to the company, the debt securities will rank as senior unsecured obligations.&nbsp;Interest payments will be made twice each year, with the first scheduled payment expected in September 2026.&nbsp;Unless the notes are converted into shares, repurchased, or redeemed earlier, they will come due on Mar. 1, 2031. If investors choose to convert the notes, CRISPR will settle the conversion by issuing common shares with a nominal value of CHF 0.03 ($0.039) each.CRISPR Therapeutics said it expects to allocate the net proceeds from the sale for broad corporate needs.&nbsp;<a href="https://stocktwits.com/symbol/CRSP">CRISPR Therapeutics stock</a> traded over 6% lower in Tuesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock changed to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">2026 Goals</h2>CRISPR Therapeutics is developing a wide range of programs in blood disorders, cancer, regenerative medicine, heart and autoimmune diseases, and other rare conditions. CASGEVY is the first CRISPR-based therapy for patients with sickle cell disease and transfusion-dependent beta thalassemia.In January, it&nbsp;outlined its strategic priorities for 2026, highlighting multiple expected milestones across its gene-editing and siRNA portfolios. It also emphasized a strong financial position, with around $2 billion in cash, cash equivalents, and marketable securities to support ongoing research and commercial activities.CRSP stock has gained over 23% in the last 12 months.&nbsp;Exchange Rate: 1CHF=1.29USDAlso See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-surged-today-what-is-fueling-the-rally/cZdovHXRI7O">CAPR Stock Surged 17% Today — What’s Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Crispr Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Is CRSP Stock Falling Pre-Market Today?

CRISPR Therapeutics AG (CRSP) on Tuesday announced plans to raise capital through a private debt offering as the gene-editing biotechnology company continues funding research and development efforts. 

Why Is CRSP (CRISPR Therapeutics) Stock Falling Pre-Market Today?

Equity

The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031.


<ul class="summary-bullets"><li>TD Cowen raised its price target on Rivian shares to $20 from $17.</li><li>The firm estimates that annual sales for R2 could eventually range from roughly 212,000 to 335,000 vehicles.</li><li>Rivian plans to price the R2 SUV at roughly $45,000 with roll-out beginning in the second-quarter.&nbsp;</li></ul>Rivian Automotive Inc. (RIVN) received a vote of confidence from TD Cowen, which upgraded the electric vehicle maker’s stock to a ‘Buy’ rating from ‘Hold’ while lifting its price target.&nbsp;TD Cowen raised its price target on Rivian shares to $20 from $17, according to TheFly.&nbsp;<h2 class="st-heading-2">R2 Growth Potential</h2>The revised outlook comes as the firm evaluated potential demand for Rivian’s upcoming R2 vehicle platform, which could significantly expand the company’s market reach.TD Cowen’s analysts estimate that demand for R2 could eventually range from roughly 212,000 to 335,000 vehicles. They noted that this projection may exceed current Wall Street expectations for 2027.&nbsp;Following the upgrade,&nbsp;<a href="https://stocktwits.com/symbol/RIVN">Rivian Automotive stock</a> traded over 4% higher in Tuesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘low’ message volume levels.&nbsp;<h2 class="st-heading-2">The Affordable R2 Lineup&nbsp;</h2>The next-generation EVs are expected to target a broader, more affordable segment of the EV market than Rivian’s current R1 lineup. By expanding into a larger customer base, Rivian aims to ramp up production and improve long-term revenue growth.Rivian plans to price the R2 SUV at roughly $45,000, cheaper than the R1 models that start around $70,000. The R2 roll-out will begin in the second-quarter (Q2).&nbsp;In its fourth-quarter (Q4) earnings call, Rivian CFO Claire McDonough noted that the operational complexity tied to the R2 rollout could put pressure on automotive gross profit in Q2 and the third quarter of 2026, even though total gross profit is expected to rise compared with the previous year.RIVN stock has gained over 57% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-ceo-jensen-huang-frames-ai-as-foundational-infrastructure-ahead-of-gtc-event-next-week/cZdotbFRI7J">Nvidia CEO Jensen Huang Frames AI As ‘Foundational Infrastructure’ Ahead Of GTC Event Next Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Rivian logo is on display during the 2025 Los Angeles Auto Show at the Los Angeles Convention Center on November 23, 2025 in Los Angeles, California

RIVN Stock Gains 4% Pre-Market After TD Cowen Upgrade: Analyst Sees Strong Demand For Upcoming R2 Models

Rivian Automotive Inc. (RIVN) received a vote of confidence from TD Cowen, which upgraded the electric vehicle maker’s stock to a ‘Buy’ rating from ‘Hold’ while lifting its price target. 

The firm believes the new lineup could significantly expand Rivian's addressable EV market.

CRISPR Therapeutics Pivots Beyond Casgevy, Highlights CTX310 Data and New Cardiovascular Push

CRISPR Therapeutics (NASDAQ:CRSP) used a fireside chat at TD Cowen's 46th Annual Healthcare Conference to outline how the company is trying to broaden its identity beyond its first commercial...

SR One Capital Management LP Has $132.13 Million Stock Position in CRISPR Therapeutics AG $CRSP

SR One Capital Management LP increased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 94.4% during the 3rd quarter, according to its most recent filing with the...

Citigroup Inc. Sells 88,203 Shares of CRISPR Therapeutics AG $CRSP

Citigroup Inc. decreased its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 59.3% in the third quarter, according to the company in its most recent disclosure with the Securities...

CRISPR Therapeutics AG $CRSP is ARK Investment Management LLC's 8th Largest Position

ARK Investment Management LLC decreased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 3.9% during the third quarter, according to the company in its most recent...

Forget CRISPR Therapeutics: This Gene Editing Player Already Boasts the Profits It Dreams Of

Key PointsCRISPR Therapeutics' gene-editing platform looks fairly promising, but plenty of challenges could sink the stock...

Is CRISPR Therapeutics Stock Too Risky to Buy Right Now?

Key PointsCRISPR obtained approval for Casgevy back in 2023, but the rollout has been slow...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $ORCL earnings Tuesday?

Stocktwits

Stocktwits Polls

The announced $350M convertible senior notes offering has triggered significant debate and concern over potential dilution and the company's financial strategy.

Widespread frustration is mounting over leadership's decision to raise capital despite a substantial cash reserve, prompting questions about their strategic vision.

Despite the recent capital raise, users continue to speculate about a potential acquisition, often mentioning an existing partner as a likely suitor.

Opportunistic traders are actively identifying and setting buy limits at discounted prices, anticipating a rebound from the recent drop.

CRSP
CRISPR Therapeutics AG

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CRSP News

CRSPCRISPR Therapeutics AG